News

Moderna falters under Trump’s second term as vaccine scepticism grows
The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling ...
Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful
Moderna's (MRNA) new COVID vaccine approval targets a broader high-risk population. Check out why I see potential for a 25-40 ...
Pfizer CEO: HHS claims of ‘concealed safety concerns’ on mRNA vaccines are ‘completely inaccurate’
Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...
Moderna (MRNA) Faces Multiple Regulatory Challenges
Bloomberg reported that the FDA recently granted Moderna Inc. (NASDAQ:MRNA) a narrower approval for its next-generation COVID ...
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...
STAT4d
Pharmalittle: We’re reading about HHS canceling a Moderna contract, FDA rejecting a rare disease drug, and more
In today's Pharmalittle roundup, we're reading about HHS canceling a Moderna contract, FDA rejecting a rare disease drug, and ...
Moderna Announces Update on Investigational Pandemic Influenza Program
H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna’s award ...